Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma.Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis.Prednisolone can effectively treat irAEs.However, it is unclear how or if nivolumab should be administer